News & Events

StageBio is Attending at STP’s 42nd Annual Symposium

StageBio is attending and presenting at the 42nd Annual Society of Toxicologic Pathology (STP) Symposium. This year’s theme, “Toxicologic Pathology of the Hepatobiliary System”, will bring attendees together to discuss new and emerging topics with keynote sessions, poster presentations and more.  The 2023 event takes place June 25-28 in Summerlin, Nevada.

Be sure to attend our sponsored Continuing Education Courses:

  • Toxicologic Neuropathology of Novel Therapeutics June 25 from 1:30-5:30pm. Dr Sarah Cramer, DVM, PhD, DACVP, Director, Medical Device & Neuropathology, StageBio will be presenting the first session, “Vector-Based and Cell-Based Therapies: How Do They Work, What Do They Target?” from 1:30pm-2:10pm. Make sure you register in advance here.
  • Communicate to Advocate: Utilizing Power Skills for All Stages of Your Career, June 25 from 1:30pm-5:30pm. Attend Dr Quinci Plumlee, DVM, MS, DACVP, Senior Pathologist, StageBio’s session, “Advocating for Yourself as an Early Career Pathologist” from 3:30-4:15pm. This session is brought to you in collaboration with the Diversity, Inclusion, and Belonging Committee and Women in Tox Path Subcommittee. Make sure you register in advance here.

If you would like to connect with StageBio during STP 2023, contact our team here.

About StageBio

StageBio is a leading provider of GLP-compliant necropsy, histology, pathology, and specimen archiving and biorepository services for the biopharmaceutical, medical device, academic, and contract research industries. The company operates four GLP laboratories as well as three GLP specimen archiving facilities in the U.S., along with one GLP laboratory in Europe. StageBio will continue to make investments in facility and technology infrastructure to meet the growing demand for high-quality histopathology services globally. StageBio has a team of 30+ board-certified veterinary pathologists and more than 100 laboratory technicians on staff supporting our unified commitment to quality, scientific integrity, and client satisfaction. Learn more at

Learn more about StageBio’s services and capabilities here.

Back to Index

Learn more about StageBio’s COVID-19 response